Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.02
-0.5%		$136.51
$77.58
▼
$156.92
$355.10B0.2110.65 million shs8.68 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.55
+3.2%		$14.50
$12.07
▼
$29.23
$14.00B-1.246.33 million shs4.27 million shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-4.22%+6.23%+20.97%+71.33%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-0.28%+25.36%+25.27%-0.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.02
-0.5%		$136.51
$77.58
▼
$156.92
$355.10B0.2110.65 million shs8.68 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.55
+3.2%		$14.50
$12.07
▼
$29.23
$14.00B-1.246.33 million shs4.27 million shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-4.22%+6.23%+20.97%+71.33%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-0.28%+25.36%+25.27%-0.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$151.325.07% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.47
Hold$25.9147.63% Upside

Current Analyst Ratings Breakdown

Latest SMMT and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$150.00 ➝ $172.00
9/9/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone logo
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
9/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$127.00 ➝ $161.00
9/8/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$33.00
9/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$146.00 ➝ $170.00
9/4/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$150.00 ➝ $170.00
9/3/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/26/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/26/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.47$11.43 per share12.60$21.22 per share6.79
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25115.2214.916.264.77%16.73%6.13%10/29/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest SMMT and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.36%+5.75%272.00%14 Years
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A

Latest SMMT and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265797.75 million131.63 millionOptionable

Recent News About These Companies

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
 |  gurufocus.comhttps://www.gurufocus.com/news/9078710/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pdl1positive-advanced-nsclc-in-akesos-harmoni2-study-condu
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China
 |  businesswire.comhttps://www.businesswire.com/news/home/20260913549808/en/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pd-l1-positive-advanced-nsclc-in-akeso%e2%80%99s-harmoni-2-study-conducted-in-china/
Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT
September 12 at 3:14 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-shares-of-120560-summit-therapeutics-plc-smmt-2026-09-12/
Summit Therapeutics PLC (SMMT)
September 10 at 12:36 AM  |  fr.investing.comhttps://fr.investing.com/equities/summit-therapeutics-plc-news
Summit Therapeutics Shares Rise After Upgrade From Jefferies
September 9, 2026  |  marketscreener.comM
Summit Therapeutics shares gain after Jefferies upgrades stock to buy
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/summit-therapeutics-shares-gain-after-jefferies-upgrades-stock-to-buy/ar-AA2bSSP1
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-time-to-buy-2026-09-09/
Summit Therapeutics PLC $SMMT Shares Bought by Wellington Management Group LLP
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-summit-therapeutics-plc-smmt-shares-bought-by-wellington-management-group-llp-2026-09-09/
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
September 8, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/summit-smmt-says-akeso-reported-a-harmoni-2-overall-survival-benefit-against-pembrolizumab-1827424/
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
September 7, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/summit-therapeutics-smmt-soars-28-on-ivonescimab-progress-1829526/
Seven Fleet Capital Management LP Acquires Shares of 73,300 Summit Therapeutics PLC $SMMT
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-acquires-shares-of-73300-summit-therapeutics-plc-smmt-2026-09-05/
Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-takes-628-million-position-in-summit-therapeutics-plc-smmt-2026-09-05/
Summit Therapeutics (NASDAQ:SMMT) Rating Increased to Hold at Wall Street Zen
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003806
Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-summit-therapeutics-nasdaq-smmt-raised-to-hold-at-wall-street-zen-2026-09-05/
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
September 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2985150/smmt-stock-soars-on-nsclc-drug-survival-data-beating-keytruda-in-china?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2985150
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.
September 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942941-summit-therapeutics-the-high-stakes-of-translating-china-clinical-data-to-the-us
Summit packs a punch for Merck's Keytruda — but not everyone is sold
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-packs-a-punch-for-mercks-keytruda-but-not-everyone-is-sold/ar-AA2bw59t
Summit Therapeutics Stock Rises 11%
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688357/summit-therapeutics-stock-rises-11.aspx
Better cancer therapy than Keytruda? Summit Therapeutics partner's Ivonescimab outperforms in lung cancer study
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/better-cancer-therapy-than-keytruda-summit-therapeutics-partners-ivonescimab-outperforms-in-lung-cancer-study/ar-AA2bvX1i
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - What's Next?
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-whats-next-2026-09-03/
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet
September 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942687-november-14-is-make-or-break-moment-for-summit-therapeuticss-cancer-bet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$144.02 -0.69 (-0.47%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$144.28 +0.26 (+0.18%)
As of 09/11/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$17.55 +0.55 (+3.24%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$17.66 +0.11 (+0.63%)
As of 09/11/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas